|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 01, 2012 ) New York, NY -- VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, identifies four healthcare companies that may be worth a 'buying look' after recent share price drops.
This is an abbreviated report. Full report available at: http://vfcsstockhouse.com/blog/article/-amarin-s-share-price-dip-and-other-healthcare-stories-to-watch-amrn-dndn-ssh-mric
Although the DOW remains trading strong at over 13,000 this week - pending the outcome of some key economic data releases that could change everything - extreme volatility still exists in some areas of the market, namely the healthcare and biotech sectors where FDA approvals for some companies and substandard earnings reports by others have largely effected the trading patterns rolling into the new month of August.
Here's a look at some of the more active movers with catalysts pending that could be worth keeping an eye on moving forward:
Amarin Corporation (AMRN): Since running to a new 52-week high of nearly sixteen dollars leading into a positive FDA approval decision for Vascepa in the treatment of very high triglycerides last week, Amarin Corp has been one of the most discussed stories out there as investors come to grips with the stock's drastic drop following a positive news release.
Dendreon (DNDN): On the subject of Dendreon, bad went to worse for the one time golden child of the sector. Shares initially collapsed about a year ago on poor earnings and questionable guidance, but the announcement of restructuring shortly thereafter sent them even lower. Another trip to the downside has materialized as another round of unremarkable sales revenue and guidance sent investors fleeing again, especially as the company announced that it would be closing its New Jersey facility and laying off more employees in an effort to trim costs. At one time, the full expansion of that Jersey facility provided a share price catalyst, and in a note of irony, its closing may be the final nail in the coffin for the company, according to some estimates.
Sunshine Heart (SSH): Dendreon may be on the dive, but the same certainly cannot be said for Sunshine Heart. This company is fresh off probably its most significant announcement to date, the announcement of CE Mark approval in Europe for the C-Pulse Heart Assist System that has proven highly effective in treating - and even reversing - the symptoms of Class III and ambulatory Class IV heart failure. That milestone news positions the company to potentially register its first commercial sales later this year, right around the same time that a definitive trial should be initiated within the United States that will set the C-Pulse up with a date with the FDA.
MRI Interventions (MRIC): MRI Interventions is another medical device play that has retreated somewhat in price after having recently spiked on solid news developments and a burst of new volume. Like Sunshine, MRI's technology goes beyond existing treatments to enable the medical community to conduct less-invasive surgical procedures. As governments around the world are looking at curbing exorbitant health care costs, it's important to note that "less-invasive" also translates into "less-costly," which likely helps to give the company an edge in finding partnerships and potential buyers.
Contact VFC's Stock House: vfc@vfcsstockhouse.com
Originally published at: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
About VFCsStockHouse.com:
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, and pharmaceutical and healthcare stocks. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
